"Frutto dell’alleanza tra soggetti pubblici e appartenenti al privato sociale, l’Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST è riferimento nazionale in campo oncologico. La sua missione consiste nel promuovere e realizzare attività di cura, studio e ricerca, in particolare ricerca traslazionale. Operativo dal 2007 all’interno delle strutture dell'ex Ospedale Civile di Meldola (Forlì-Cesena) ha sedi a Forlì, Cesena e Ravenna (Radioterapia) ed è riconosciuto quale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)."

During the past decade, Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori conducted 249 clinical trials. In the 10-year time frame, 249 clinical trials started and 76 clinical trials were completed, i.e. on average, 30.5% percent of trials that started reached the finish line to date. In the past 5 years, 114 clinical trials started and 57 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori" #1 sponsor was "Hoffmann-La Roche" with 43 trials, followed by "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori" with 37 trials sponsored, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 12 trials sponsored, "Incyte Corporation" with 12 trials sponsored and "Janssen Research & Development, LLC" with 12 trials sponsored. Other sponsors include 182 different institutions and companies that sponsored additional 103 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori" #1 collaborator was "Merck Sharp & Dohme LLC" with 6 trials as a collaborator, "AbbVie" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator, "Clinical Research Technology S.r.l." with 4 trials as a collaborator and "Breast International Group" with 3 trials as a collaborator. Other collaborators include 125 different institutions and companies that were collaborators in the rest 105 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori" are "Breast Cancer" (12 trials), "Carcinoma, Non-Small-Cell Lung" (12 trials), "Prostate Cancer" (11 trials), "Acute Myeloid Leukemia" (8 trials) and "Chronic Lymphocytic Leukemia" (8 trials). Many other conditions were trialed in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori" in a lesser frequency.

Most popular intervention types in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori" are "Drug" (262 trials), "Other" (31 trials), "Biological" (23 trials), "Procedure" (8 trials) and "Radiation" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Atezolizumab" (24 trials), "Carboplatin" (18 trials), "Paclitaxel" (17 trials) and "Nivolumab" (15 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori" are 251 trials for "All" genders, 32 trials for "Female" genders and 19 trials for "Male" genders.

Currently, there are NaN active trials in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori". 1 are not yet recruiting, 67 are recruiting, 82 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 88 completed trials in Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori, undefined suspended trials, and 30 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori, 40 "Phase 1" clinical trials were conducted, 108 "Phase 2" clinical trials and 133 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 13 trials that are defined as “Not Applicable".

Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori has several departments that took part in Clinical trials: "UO Oncologia Medica IRCCS IRST" - 16 trials, "UO Immunoterapia e laboratorio TCS, IRST IRCCS" - 2 trials, "UO Radiologia" - 2 trials, "Laboratorio Farmaci Antiblastici" - 2 trials